AUTHORS
chaunyun wang, xiaoling wang2, zhenzhen wang3, hailong liu4, pengfei tao5, chengfei Yang6, Yingyong Xu, MD, PhD, MBA7, yixuan zhou8, zhihong Lv9, kaijing sun10, Heng Mei, MD, PhD11, Luhan Yang, PhD12
AFFILIATIONS
1 Qihan Biotechnology, Hangzhou, China
2 Qihan Biotechnology, Hangzhou, China
3 Qihan Biotechnology, Hangzhou, China
4 Qihan Biotechnology, Hangzhou, China
5 Qihan Biotechnology, Hangzhou, China
6 Qihan Biotechnology, Hangzhou, China
7 Qihan Biotechnology, Hangzhou, China
8 Qihan Biotechnology, Hangzhou, China
9 Qihan Biotechnology, Hangzhou, China
10 Qihan Biotechnology, Hangzhou, China
11 Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, wuhan, China
12 Qihan Biotechnology, Hangzhou, China
ABSTRACT
Background Commercializing in vivo CAR-T therapy shifts the demands on lentiviral vector (LV) supply: rather than one patient-specific batch, it requires large volumes of consistent, immune-compatible vector at a viable cost of goods. Conventional adherent packaging scales poorly and is a persistent source of batch-to-batch variability, while vector particles inherit the membrane identity of the packaging cell - driving complement activation, phagocytic clearance, and exposure of non-T cells. Macroi-293 was developed to resolve both constraints in a single cell line: an advanced, multiplex gene-edited monoclonal 293T-derived packaging line designed to confer an engineered, immune-evasive vector surface and adapted to serum-free suspension culture for commercial-scale production. As the field advances toward in vivo CAR-T strategies — which demand orders of magnitude more viral vector than ex vivo CAR-T approaches —a well-defined, scalable, and cost-effective LV manufacturing platform becomes a prerequisite for clinical translation and commercial viability.
Methods The monoclonal line was established by multiplex gene editing and secured in a three-tier bank (PCB → MCB → WCB). It was adapted to both adherent and serum-free suspension formats, with clonal identity, engineered-protein expression, growth, and vector productivity monitored across extended passaging.A closed, scalable purification train was configured for each format. Vector particles were assessed for incorporation of the engineered membrane proteins and benchmarked against a conventional packaging system and an independently engineered reference line using serum neutralization assay, circulating vector persistence measurement, tissue biodistribution analysis, and a humanized tumor-bearing mouse model.
Critically, the same clonal cell line was successfully adapted to suspension culture — a capability that addresses the most significant scalability barrier in LV manufacturing. Comprehensive passage stability studies were conducted for both adherent and suspension formats. Parallel LV production processes were developed and characterized for each platform, including upstream packaging and downstream purification workflows.
Results Macroi-293 retained its engineered phenotype, clonal identity, and productivity throughout extended passaging in both formats. The engineered proteins were detected on vector particles, confirming transfer of the designed surface from cell to vector. Suspension adaptation substantially increased volumetric titer and, combined with larger working volumes, markedly raised clinical doses per batch. Vectors retained activity after serum exposure, showed favorable circulating persistence and restricted tissue distribution. In humanized tumor-bearing mice, these vectors generated circulating CAR-T cells with durable tumor control and good tolerability, with performance comparing favorably with both reference production systems. The suspension platform demonstrated a clear advantage in manufacturing scalability, supporting batch volumes compatible with multi-patient clinical supply from a single production run — a critical requirement for commercial-scale and in vivo CAR-T programs where vector demand far exceeds current industry capacity.
Conclusions Macroi-293 combines an immune-compatible engineered vector surface with a suspension platform that scales — lowering process complexity and cost of goodsand providing a path from early-phase to commercial supply without any change in cell line identity. This platform enables manufacturers to meet the grwoing demand for high-quality LV at commercial scale.
DISCLOSURES
Luhan Yang, PhD: No relevant conflicts of interest to declare.